证券研究报告 南方航空(600029.SH) 投资评级： 买入（首次） ——枢纽网络优势巩固，复苏弹性有望释放 孙延 SAC：S1350524050003 sunyan01@huayuanstock.com 曾智星 SAC：S1350524120008 zengzhixing@huayuanstock.com 王惠武 SAC：S1350524060001 wanghuiwu@huayuanstock.com 张付哲 SAC：S1350525070001 zhangfuzhe@huayuanstock.com 联系人 交通运输 | 航空机场 非金融|首次覆盖报告 证券分析师 hyzqdatemark 2026 年 01 月 29 日 投资要点： 风险提示。人民币汇率波动，油价上涨，出行需求不及预期，地缘政治风险。 | | 盈利预测与估值（人民币） | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 8.28/5.35 | | 2023 | 2024 | 2025E | 2026E | 2027E | | | 营业收入（百万元） | 159,929 ...

证券研究报告 商贸零售 | 互联网电商 非金融|公司点评报告 hyzqdatemark 2026 年 01 月 29 日 | 基本数据 | | | | 2026 | 年 | | 日 | | | 27 | | 01 | 月 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 收盘价（元） | | | | | | | 38.25 | | | | | | | | 一 年 低 | 最 | 高 | 最 | | | / | | | | | 内 | | | | （元） | | | | | | | | | 82.50/26.60 | | | | | | 总市值（百万元） | | | | | | | | 11,898.02 | | | | | | | 流通市值（百万元） | | | | | | | 8,649.94 | | | | | | | | 总股本（百万股） | | | | | | | 311.06 | | | | | | | | 资产负债率（%） | | | | | | | 56.52 | | ...

证券研究报告 交通运输 | 航运港口 港股|公司点评报告 hyzqdatemark 2026 年 01 月 29 日 证券分析师 孙延 SAC：S1350524050003 sunyan01@huayuanstock.com 曾智星 SAC：S1350524120008 zengzhixing@huayuanstock.com 王惠武 SAC：S1350524060001 wanghuiwu@huayuanstock.com 张付哲 SAC：S1350525070001 zhangfuzhe@huayuanstock.com 33.00/15.70 风险提示。美国关税政策变化；经济增长不及预期；红海复航；美国对航运港口相 关政策的变化；地缘政治风险。 | 资产负债率（%） | 22.55 | 盈利预测与估值（美元） | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 资料来源：聚源数据 | | | 2023 | 2024 | 2025E | 2026E | 2027E | | | | 营业收入（百万美元） | 2,429 | 3,05 ...

Group 1: New Consumption - Beauty Industry Insights - The GMV of cosmetics on WeChat Video Account is projected to reach 12.18 billion yuan in 2025, with domestic brands expected to dominate the channel [5][6] - In 2025, domestic brands are anticipated to hold an 80.4% market share on WeChat Video Account, with top brands like Zheng Mingming and Lin Qingxuan leading the sales [6][7] - Skincare products are expected to capture 68.9% of the market share in the WeChat Video Account channel, indicating a higher premium potential compared to other categories [6][7] Group 2: WeChat Video Account as a Competitive Platform - WeChat Video Account is seen as a new battleground for beauty brands, offering a unique advantage by integrating public and private domains, allowing brands to retain users for long-term engagement [7] - The beauty-related voice volume in the WeChat ecosystem reached 10.39 million from October 2024 to September 2025, marking a 48% year-on-year growth, with video account voice volume increasing by 121.9% [7] - The platform's clear commercialization logic and empowerment system provide beauty brands with sustainable growth opportunities, making it crucial for brands to establish a presence on this platform [7] Group 3: Pharmaceutical Industry - Fuyuan Pharmaceutical Overview - Fuyuan Pharmaceutical, established in 1999 and listed in 2022, focuses on generic drugs and is expanding into innovative drugs, with a robust portfolio of 209 domestic drug registrations [13][14] - The company reported a revenue of 3.209 billion yuan from drug formulations in 2024, with a compound annual growth rate (CAGR) of 7.75% from 2019 to 2024, indicating stable growth [14][15] - Fuyuan is strategically investing in small nucleic acid innovative drugs, with 23 patents filed, and its core pipeline includes FY101, which is in Phase I clinical trials, targeting a large market of patients with dyslipidemia [15][16] Group 4: Financial Projections for Fuyuan Pharmaceutical - The company is expected to achieve net profits of 465 million yuan, 481 million yuan, and 520 million yuan from 2025 to 2027, with growth rates of -5%, 4%, and 8% respectively [16] - The current price-to-earnings (PE) ratios for these years are projected at 30X, 29X, and 27X, indicating a favorable valuation compared to peers [16]

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [5][8]. Core Viewpoints - The company is a leader in China's egg product processing industry, with strong B-end customer relationships and significant technological barriers. The C-end market is expected to open up new growth opportunities [5][10]. - The Chinese egg product processing market is projected to exceed 50 billion yuan in 2024, with steady growth in downstream demand [7][33]. - The company has established long-term partnerships with major clients such as Unilever and Yum, driving growth through capacity expansion and innovation [10][57]. Summary by Sections 1. Business Overview - The company focuses on the development, production, and sales of liquid eggs, egg powder, and various egg-based prepared products, being a key player in agricultural industrialization [15][18]. - The company has four production bases in China and has been a pioneer in the egg product processing industry, ensuring product quality and safety [15][18]. 2. Industry Analysis - The Chinese egg product processing market is expected to grow significantly, with a market size surpassing 50 billion yuan in 2024 and a year-on-year growth rate of 7% [33][52]. - The processing rate of eggs in China is currently only 5%-7%, indicating substantial room for growth compared to developed countries [44][52]. 3. Customer Relationships and Innovation - The company has established strong ties with major clients, including Unilever and Yum, and is focused on expanding its capacity and enhancing its R&D capabilities [10][57]. - The company has launched innovative products such as egg white functional drinks, targeting both fitness enthusiasts and specific demographics like the elderly [66][68]. 4. Financial Forecast and Valuation - The company is expected to achieve a net profit of 0.89 billion yuan in 2025, with corresponding P/E ratios of 25.8, 22.9, and 20.5 for 2025-2027 [6][8]. - Revenue from liquid eggs is projected to grow steadily, while egg powder and prepared products are also expected to see recovery and growth [9].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [4]. Core Views - The company is a leading enterprise in titanium processing materials, with an expected increase in demand from consumer electronics and new layouts in titanium alloy powder, which are anticipated to drive long-term growth [4][5]. - The company is transitioning from rough processing to precision and deep processing, expanding into emerging markets such as consumer electronics and 3D printing [5]. - The company has established strong partnerships with key clients in the chemical and energy sectors, focusing on the development of new customers in various fields [5]. Financial Performance - The company achieved a revenue of 450 million yuan in the first three quarters of 2025, with a projected revenue of 800 million yuan and a net profit of 170 million yuan for 2024 [5][6]. - The expected revenue for 2024 is 800 million yuan, with a net profit of 172 million yuan, and for 2025, the revenue is projected to be 594 million yuan with a net profit of 127 million yuan [7]. - The company anticipates a significant increase in revenue to 1.27 billion yuan by 2027, with a corresponding net profit of 299 million yuan [6][7]. Industry Insights - The titanium processing material production in China is expected to reach 172,000 tons in 2024, with a year-on-year growth of 8.1% [5]. - The global titanium processing material production is projected to be around 260,000 tons in 2024, reflecting an 8% increase from the previous year [5]. - The main applications for titanium and titanium alloy products include chemical, aerospace, and consumer electronics sectors, with the largest consumption in chemicals at 73,000 tons [5]. Growth Potential - The company is actively expanding its titanium alloy powder business, which is expected to open up new growth opportunities in additive manufacturing for aerospace and medical applications [5][6]. - The company has plans to achieve an annual production capacity of 1,000 tons for titanium powder, which will support various applications in consumer electronics, aerospace, and medical devices [6].

Group 1: AI Energy Sector - The AI energy sector has seen significant catalysts recently, with uranium prices continuing to rise, reaffirming investment opportunities in this sector. The World Nuclear Association's report indicates that if governments meet their nuclear power construction goals, global nuclear capacity could reach 1,446 GW by 2050, exceeding the previous target of 1,200 GW [5][11] - To achieve the 1,446 GW target by 2050, a structured annual grid connection rhythm is required, with specific capacity targets set for different periods: 14.4 GW from 2026 to 2030, 22.3 GW from 2031 to 2035 (a 55% increase), 49.2 GW from 2036 to 2040 (doubling), and 65.3 GW from 2046 to 2050 [12][11] - The report emphasizes that nuclear power and uranium are transitioning from "optional energy" to "strategic necessities," which is expected to enhance their long-term pricing power, cash flow stability, and capital attractiveness [12] Group 2: Financial Technology Sector - The financial technology sector experienced a downturn this week, with most stocks under pressure. Credicorp led the gains with a 7.0% increase, following the announcement that its digital banking subsidiary, Tenpo, received operational approval in Chile, making it the first licensed new bank under Chile's banking law [14][16] - Capital One announced plans to acquire fintech company Brex for approximately $5.15 billion, aiming to expand its presence in corporate payments and expense management, reflecting the trend of traditional financial systems integrating with new technologies [16][17] - Interactive Brokers reported Q4 2025 earnings that exceeded market expectations, with a 15.4% year-on-year revenue increase to $1.64 billion, and a non-GAAP EPS of $0.65, surpassing general market forecasts by 11% [17] Group 3: Quantum Computing Sector - D-Wave announced the completion of its acquisition of Quantum Circuits Inc., solidifying its position as the only dual-platform quantum computing company globally. This acquisition enhances D-Wave's capabilities in error correction, crucial for commercializing gate model quantum computers [21][22] - The market saw fluctuations, with top gainers including Oxford Instruments (+3.9%) and Microsoft (+1.3%), while D-Wave experienced a significant drop of 11.1% [19][20] - The report highlights that D-Wave's acquisition addresses a critical shortcoming in the gate model route, with the dual-track qubit being a key asset for accelerating error correction, indicating a clearer timeline for the gate model project's deliverables [22] Group 4: Commercial Aerospace Sector - The aerospace sector experienced a slight pullback this week, with major indices showing declines, including a 1.9% drop in the US Space Economy Index and a 3.2% decline in the S&P Aerospace and Defense Select Industry Index [24] - Blue Origin announced its TeraWave project, which aims to provide up to 6 Tbps of symmetrical data transmission rates globally, utilizing a constellation of 5,408 interconnected satellites. This project is designed to meet the connectivity needs of businesses and government users, particularly in remote areas [26][27] - GE Aerospace reported Q4 earnings that slightly exceeded market expectations, but the stock fell due to a notable decline in operating profit margins in its core commercial engine business [24]

Investment Rating - The report assigns an investment rating of "Buy" for the company, indicating a positive outlook based on its stable generics business and growth potential in small nucleic acid drugs [5]. Core Insights - The company has a solid foundation in generics, with a stable growth phase, and is strategically positioning itself in the small nucleic acid innovation space, which is expected to drive long-term growth [7][10]. - The generics business is projected to maintain steady cash flow, while the innovative drug segment is anticipated to create a second growth curve, enhancing the company's overall valuation [8][10]. Summary by Relevant Sections Market Performance - The closing price of the company's stock is 28.82 yuan, with a market capitalization of 13,833.60 million yuan [3]. Financial Forecast and Valuation - Revenue projections for 2023 to 2027 are as follows: 3,340 million yuan (2023), 3,446 million yuan (2024), 3,472 million yuan (2025E), 3,852 million yuan (2026E), and 4,266 million yuan (2027E) [6]. - The expected growth rates for revenue are 3.07% (2023), 3.17% (2024), 0.75% (2025), 10.95% (2026), and 10.74% (2027) [6]. - The projected net profit for the same years is 489 million yuan (2023), 489 million yuan (2024), 465 million yuan (2025), 481 million yuan (2026), and 520 million yuan (2027) [6]. - The company’s price-to-earnings (P/E) ratios are estimated at 28.30 (2023), 28.31 (2024), 29.78 (2025), 28.76 (2026), and 26.61 (2027) [6]. Business Overview - The company, formerly known as Wansheng Pharmaceutical, has been in the generics business for over 20 years and has recently expanded into innovative drugs, particularly small nucleic acids [7]. - As of the first half of 2025, the company holds 209 domestic drug registration approvals, with a revenue contribution of 32.09 billion yuan from drug formulations, accounting for 93% of total revenue [7][20]. - The company’s core therapeutic areas include cardiovascular, diabetes, digestive, skin diseases, and chronic kidney disease, which collectively contribute 77% of its revenue [20]. Growth Drivers - The generics business is entering a stable growth phase, with a compound annual growth rate (CAGR) of 7.75% from 2019 to 2024 [10]. - The company is actively investing in small nucleic acid drugs, with R&D expenses increasing from 180 million yuan in 2021 to 417 million yuan in 2024 [10][49]. - The N-ER platform for nucleic acid drug delivery has been established, supporting multiple projects in clinical development [50]. Competitive Position - The company has successfully navigated the challenges posed by national drug procurement policies, with a significant portion of its core products already included in procurement programs [32][43]. - The upcoming unified procurement for previously selected products is expected to stabilize cash flow and enhance the company's competitive position in the generics market [42][43].

资料来源：聚源，华源证券研究所，截至2026年01月27日 华源晨会精粹 20260127 金融工程 资金流向混债二级基金，周期和大金融占比提升——主动型公募基金 2025 年四季报分析：2025 年四季度公募基金总规模变动不大，但不同类别的基金 规模发生明显切换：投资者因追求稳健收益，资金从高波动的主动权益基金（较上 季度规模缩减 1823 亿元）和低风险的纯债基金（较上季度规模缩减 868 亿元）流出， 向中低风险的含权债基（较上季度规模增加 2398 亿元）迁移，与此同时，含权债基 的新发热度升高，发行数量创下 2020 年以来单季度新高。主动权益基金：对港股的 配置热情明显下降，显著增配周期板块。行业维度上，电子、通信、电新为重仓前 三，有色金属、基础化工和非银主动加仓最多。股债混合型基金：同样呈现出减仓 港股、加仓创业板的特征，2025 年四季度重仓股中占比最高的三个行业分别为电子、 有色和通信，主动加仓最多的行业为电子、通信和非银。含权债基：是承接资金向 中低风险迁移的重要方向，权益配置上向周期和大金融倾斜，对医药板块的减仓幅 度较大；债券方面，持续降低可转债仓位，转向利率债和信用债。纯债基金：是 ...

证券研究报告 房地产 行业定期报告 hyzqdatemark 2026 年 01 月 27 日 证券分析师 邓力 SAC：S1350525070006 dengli@jzsec.com 陈颖 SAC：S1350525110002 chenying02@huayuanstock.com 唐志玮 tangzhiwei@huayuanstock.com 二手房成交回暖，《求是》发文提及城市更新 投资评级： 看好（维持） ——房地产行业周报（26/1/17-26/1/23） 投资要点： 风险提示：房地产量价超预期下行、房地产融资资金趋紧、房地产政策不及预期。 请务必仔细阅读正文之后的评级说明和重要声明 板块行情：本周上证指数上升 0.8%、深证成指上升 1.1%、创业板指下跌 0.3%、沪深 300 下 跌 0.6%、房地产（申万）上升 5.2%。个股方面，涨跌幅前五的分别为：*ST 荣控(+15.8%)、 顺发恒能(+15.7%)、城投控股(+14.9%)、大悦城(+14.4%)、珠免集团(+12.6%)，涨跌幅后五 的分别为：城建发展(-6.0%)、中洲控股(-2.8%)、电子城(-2.1%)、特发服务(-1.9 ...